ACAD

ACADIA Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

22.660

+0.04(0.177%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

22.660

Open

22.660

VWAP

Vol

Mkt Cap

3.79B

Low

22.660

Amount

EV/EBITDA(TTM)

30.53

Total Shares

165.22M

3.10B

EV/OCF(TTM)

20.84

P/S(TTM)

3.79

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

283.52M

+9.21%

0.128

-85.15%

274.33M

+9.56%

0.134

-33.13%

262.55M

+8.51%

0.137

-31.6%

Estimates Revision

The market is revising Upward the revenue expectations for ACADIA Pharmaceuticals Inc. (ACAD) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by 56.76%.

Revenue Estimates for FY2025

Revise Upward

+0.06%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-18.3%

In Past 3 Month

Stock Price

Go Up

+56.76%

In Past 3 Month

19 Analyst Rating

28.24% Upside

Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 29.06 USD with a low forecast of 15.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

5 Hold

1 Sell

Moderate Buy

28.24% Upside

Current: 22.660

Low

15.00

Averages

29.06

High

39.00

28.24% Upside

Current: 22.660

Low

15.00

Averages

29.06

High

39.00

Oppenheimer

Matthew Hershenhorn

Perform

maintain

$19 -> $22

2025-06-26

Reason

Oppenheimer

Matthew Hershenhorn

Price Target

$19 -> $22

2025-06-26

maintain

Perform

Reason

Oppenheimer analyst Matthew Hershenhorn raised the firm's price target on Acadia Pharmaceuticals to $22 from $19 and keeps a Perform rating on the shares. Oppenheimer was impressed by new details and overall strategy shared at Acadia's inaugural R&D Day, and sees incremental insights as supporting potential longer-term value, the analyst tells investors in a research note. The firm remains cautiously optimistic pending further derisking and appreciates Acadia's comments on prioritizing R&D efficiency and BD strategy.

RBC Capital

Outperform

maintain

$26 -> $38

2025-06-23

Reason

RBC Capital

Price Target

$26 -> $38

2025-06-23

maintain

Outperform

Reason

JPMorgan

Overweight

maintain

$26 -> $30

2025-06-06

Reason

JPMorgan

Price Target

$26 -> $30

2025-06-06

maintain

Overweight

Reason

BofA

Neutral

maintain

$18 -> $23

2025-06-05

Reason

BofA

Price Target

$18 -> $23

2025-06-05

maintain

Neutral

Reason

BofA raised the firm's price target on Acadia Pharmaceuticals to $23 from $18 and keeps a Neutral rating on the shares. Acadia recently announced the Delaware District Court ruled in favor of the company for the ongoing Nuplazid 34mg formulation patent litigation, which confirms patent protection for Nuplazid 34mg capsule into 2038, the analyst tells investors in a research note. The update removes a long-term revenue overhang for Nuplazid franchise, but additional growth from here will require a reacceleration of the Daybue launch, which has yet to be fully de-risked despite an encouraging Q1, the firm says.

Deutsche Bank

Hold

Buy

upgrade

$20 -> $35

2025-05-21

Reason

Deutsche Bank

Price Target

$20 -> $35

2025-05-21

upgrade

Hold

Buy

Reason

Morgan Stanley

Sean Laaman

Equal Weight

maintain

$20 -> $24

2025-05-20

Reason

Morgan Stanley

Sean Laaman

Price Target

$20 -> $24

2025-05-20

maintain

Equal Weight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Acadia Pharmaceuticals to $24 from $20 and keeps an Equal Weight rating on the shares after the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its '721 formulation patent for Nuplazid. This ruling now provides patent protection into 2038, notes the analyst, who had previously modelled a decline from 2030. The firm's new price target suggests an additional about $4.3B in cumulative sales post-2030, the analyst noted.

See All Ratings

Valuation Metrics

The current forward P/E ratio for ACADIA Pharmaceuticals Inc (ACAD.O) is 44.43, compared to its 5-year average forward P/E of -12.50. For a more detailed relative valuation and DCF analysis to assess ACADIA Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.50

Current PE

44.43

Overvalued PE

68.73

Undervalued PE

-93.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

64.40

Current EV/EBITDA

30.98

Overvalued EV/EBITDA

373.74

Undervalued EV/EBITDA

-244.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.79

Current PS

3.58

Overvalued PS

9.35

Undervalued PS

2.22